---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-224080"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2026-05-14T20:17:07+00:00"
generated_at: "2026-05-14T20:47:18.977542+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M

## Summary
- Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.
- Net loss $3.5M vs $2.4M a year ago; cash $12.4M with runway into H2 2027.
- Active commercial cancer centers grew to 16 from 8 at year-end 2025; target 36 by year-end 2026.
- Phase III TIGeR-PaC enrollment at 106 of 114 patients (93%); full enrollment expected by June 2026.
- FY 2026 revenue guidance reaffirmed at $3-4 million.

## SEC filing metadata
- accession: 0001193125-26-224080
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2026-05-14T20:17:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/0001193125-26-224080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/rnxt-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-224080
- JSON: https://secwatch.observer/filing/0001193125-26-224080.json
- Plain text: https://secwatch.observer/filing/0001193125-26-224080.txt

## Key facts
- Earnings Releases
  RenovoRx, Inc. reported the first quarter ended March 31, 2026 results: revenue $563,000.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $563,000
  - Result: reported results
  source text: herein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMPTM Therapy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/0001193125-26-224080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.